NK Cell Therapy for Solid Tumors from Japan
Natural killer (NK) cells from peripheral blood, cytokine-activated and expanded for adoptive transfer in treating melanoma and other solid tumors. As modified cell cultures for cancer immunotherapy, they classify under HTS 3002.51.00.00 cell therapy products. These cells directly lyse tumor targets without prior sensitization.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Patented pharmaceutical articles that are the product of Japan, of a European Union member country, of South Korea, of Switzerland, or of Liechtenstein as provided for in subdivisions (c) and (f) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
9903.05.900%Articles of aluminum, of steel or of copper or derivative aluminum or steel articles; passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; parts of passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; medium- and heavy-duty vehicles; parts of medium- and heavy-duty vehicles; wood products; patented pharmaceutical articles; and semiconductor articles, as provided in subdivision (f) of U.S. note 52 to this subchapter
Import Tips
• Provide cytokine activation protocols and flow cytometry data confirming NK phenotype
• Use validated cryopreservation media to ensure >70% post-thaw viability
• Avoid bulk import without patient-matching; declare as personalized medicine